The latest price target for Assembly Biosciences (NASDAQ:ASMB) was reported by Jefferies on September 20, 2024. The analyst firm set a price target for $35.00 expecting ASMB to rise to within 12 months (a possible 80.13% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Assembly Biosciences (NASDAQ:ASMB) was provided by Jefferies, and Assembly Biosciences upgraded their buy rating.

The last upgrade for Assembly Biosciences Inc happened on September 20, 2024 when Jefferies raised their price target to $35. Jefferies previously had a hold for Assembly Biosciences Inc.

The last downgrade for Assembly Biosciences Inc happened on October 24, 2022 when Truist Securities changed their price target from $11 to $2 for Assembly Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Assembly Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Assembly Biosciences was filed on September 20, 2024 so you should expect the next rating to be made available sometime around September 20, 2025.

While ratings are subjective and will change, the latest Assembly Biosciences (ASMB) rating was a upgraded with a price target of $2.00 to $35.00. The current price Assembly Biosciences (ASMB) is trading at is $19.43, which is within the analyst’s predicted range.